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1058Vascular Inflammation and Repair
Implications for Re-Endothelialization, Restenosis, and Stent Thrombosis
The cellular and molecular processes that control vascular injury responses after percutaneous coronary intervention in-
volve a complex interplay among vascular cells and progenitor cells that control arterial remodeling, neointimal prolifera-
tion, and re-endothelialization. Drug-eluting stents (DES) improve the efﬁcacy of percutaneous coronary intervention by
modulating vascular inﬂammation and preventing neointimal proliferation and restenosis. Although positive effects of
DES reduce inﬂammation and restenosis, negative effects delay re-endothelialization and impair endothelial function. De-
layed re-endothelialization and impaired endothelial function are linked to stent thrombosis and adverse clinical out-
comes after DES use. Compared with bare-metal stents, DES also differentially modulate mobilization, homing, and differ-
entiation of vascular progenitor cells involved in re-endothelialization and neointimal proliferation. The effects of DES on
vascular inﬂammation and repair directly impact clinical outcomes with these devices and dictate requirements for ex-
tended-duration dual antiplatelet therapy. (J Am Coll Cardiol Intv 2011;4:1057–66) © 2011 by the American College of
Cardiology Foundationr
I
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MDrug-eluting stents (DES) substantially reduce angio-
graphic and clinical restenosis by 70% across broad patient
and lesion subsets and decrease repeat target lesion inter-
ventions. The prototypical antiproliferative DES agents
sirolimus (CYPHER stent, Cordis, Miami Lakes, Florida),
paclitaxel (Taxus stent, Boston Scientific, Natick, Massa-
chusetts), zotarolimus (Endeavor stent, Medtronic, Minne-
apolis, Minnesota), and everolimus (Xience stent, Abbott
and Boston Scientific) have potent antimitotic actions that
strongly inhibit smooth muscle proliferation and matrix
production (1–3) and thus reduce neointimal formation and
restenosis. Despite efficacy in reducing neointimal prolifer-
ation and restenosis, DES failure and restenosis still occurs
and is more frequent in the settings of diabetes mellitus and
during treatment of restenotic lesions, bypass grafts, and
bifurcations (4–6). In addition to restenosis, concern has
arisen about the potential for late thromboses or very late
thromboses after DES implantation, and this concern has
led to extended-duration dual antiplatelet therapy (7–9).
Mechanisms of stent thrombosis might vary, depending on
the timing of the event (10). Acute stent thrombosis (within
24 h of implantation) and early stent thrombosis (within 30
days) are likely related to mechanical issues with the stent,
inadequate platelet inhibition, or pro-thrombotic patient
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and very late stent thrombosis (after 1 year) have been
attributed to delayed re-endothelialization and inhibition of
vascular repair. The potential for delayed re-endothelialization
and inhibition of vascular repair is particularly important after
implantation of DES, because the antiproliferative agents used
to prevent smooth muscle cell proliferation also delay re-
endothelialization in the stented segment (11,12). Angioscopic
(13) and pathological (11,12,14,15) evidence suggests that
there is delayed arterial healing with DES, compared with
bare-metal stents (BMS), because DES-treated arteries have
more histological evidence of incomplete re-endothelialization,
chronic inflammatory cell infiltration, fibrin deposition, and
platelet activation. It is important to recognize that inflamma-
tory and thrombotic pathways share common signaling path-
ways and that inflammatory responses promote activation of
the clotting cascade and stimulate platelet activation (reviewed
in Croce and Libby [16]). Experimental studies also suggest
that delayed arterial healing and DES-associated inflammation
is greatest at sites of overlapping DES with placement of
multiple stents (17). The finding of increased inflammation in
areas of stent overlap suggests a possible molecular mechanism
to explain higher stent thrombosis rates that are associated with
overlapping stents.
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1059In addition to antiproliferative drug-associated delayed
healing with DES, stent-induced or polymer-induced in-
flammation has also been identified as a possible contributor
to stent thrombosis, especially because late and very late
stent thrombosis occurs long after antiproliferative dugs
have been eluted from the polymer (18–20). Inflammatory
responses to drug, stent, or polymer might result from
nonspecific innate immune responses, which have a pre-
dominance of monocyte/macrophage infiltrates, or might be
related to antigen-specific adaptive immune hypersensitivity
responses typified by infiltration of eosinophils, B-cells, and
T-cells (reviewed in Byrne et al. [21]). Several studies have
also implicated DES-polymer-induced inflammation in the
pathobiology of restenosis and stent thrombosis (18,19).
Currently, the 4 stent platforms approved for use by the
U.S. Food and Drug Administration use different nonerod-
ible polymeric coatings for drug delivery, and experimental
animal studies suggest that biological compatibility, immu-
nogenicity, and thrombogenicity might vary among specific
polymeric compounds (22). The next generations of DES
represent an attempt to reduce the possibility of polymer-
induced inflammation, delayed arterial healing, restenosis,
and stent thrombosis through use of polymers that have
better biocompatibility and/or are biodegradable.
Emerging evidence indicates that compared to BMS,
DES impair endothelial function in arterial segments distal
to the stented site (23,24). Even 6 months after implanta-
tion of DES, artery segments distal to the DES show
abnormal vasoreactivity (25–27). DES-associated abnor-
malities in endothelial function could be related to delayed
vascular repair and not the DES drug itself, because the
kinetics of DES are such that the drugs are completely
eluted within months after implantation (28–31). It is
possible, however, that in certain circumstances drug accu-
mulation in the arterial wall (32) and the lipophilic core of
stented atheroma results in prolonged drug retention/release
and ongoing vascular dysfunction. The mechanism of DES-
associated endothelial dysfunction is not established, and
recent studies have demonstrated that there is variability in
the severity of DES-associated endothelial dysfunction
among specific DES agents (33–35). It is unclear whether
DES-associated vascular dysfunction influences clinical out-
comes after DES implantation. One small study demon-
strated impaired endothelial function in patients presenting
with in-stent restenosis, compared with matched control
subjects (36); however, this association will require valida-
tion in larger prospective investigations.
Because of the potential for delayed re-endothelialization
and repair with DES, concern was raised about possible
increased mortality and late stent thrombosis following
DES implantation (reviewed in Garg and Mauri [7]).
Because of the insufficient power of individual trials to assess
the low-incidence events of late and very late stent throm-
bosis, multiple meta-analyses were performed to evaluatethe risk of stent thrombosis in patients treated with DES
versus BMS (37– 41). These meta-analyses and subse-
quent analyses of stent registry data (42– 45) demon-
strated nearly equivalent risk of stent thrombosis (ap-
proximately 0.5%) in patients treated with DES or BMS.
A small increase in the risk of late and very late stent
thrombosis on the order of 1% to 2% cannot be excluded,
however, because available data have insufficient power to
evaluate this very rare event.
Analyses of stent thrombosis and outcomes with DES are
further complicated by significant differences in stent struc-
ture, drug delivery polymers, and antiproliferative drugs
among the rapidly expanding panel of DES. In addition,
complex biology controls vascular repair after percutaneous
coronary intervention (PCI). Understanding the common
and differential molecular pathways that regulate re-
endothelialization versus restenosis will provide a biological
context for rational use of DES and will enable development
of new DES technologies that can inhibit neointimal
proliferation and preserve or
even promote endothelial repair.
In the following sections, we
will highlight key cellular and
molecular pathways that regu-
late vascular injury and repair
in the setting of percutaneous
coronary revascularization, and
we will discuss the role of DES
in modulating vascular repair
processes.
Role of Inflammation
in Restenosis and
Vascular Repair
Stent placement leads to mechanical injury that induces
substantial local inflammation, which stimulates vascular
smooth muscle cell proliferation and extracellular matrix
deposition, resulting in neointimal thickening and resteno-
sis (46,47). Vascular inflammation after PCI involves com-
plex interactions between multiple vascular cell types, and
under normal circumstances, the cellular and molecular
processes that control vascular injury responses direct repair
and vascular healing. In pathological conditions, dysregula-
tion of vascular repair results in persistent vascular inflam-
mation, neointimal proliferation, and restenotic obstruction
of the stent lumen.
Immediately after PCI, platelets, neutrophils, and mono-
cytes play a central role in the initial inflammatory response
(47,48). Platelets and fibrin deposit on the de-endothelialized
vessel wall and recruit leukocytes to the injured vessel
segment through a cascade of cell adhesion molecules that
direct leukocyte attachment and transmigration across
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EPC  endothelial progenitor
cell
G-CSF  granulocyte colony-
stimulating factor
PCI  percutaneous
coronary intervention
SDF  stromal cell-derived
factor
SMPC  smooth muscle
progenitor cellsurface-adherent platelets (49). The initial tethering and
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1060rolling of leukocytes on platelets is mediated through
binding of the leukocyte receptor P-selectin glycoprotein
ligand-1 to platelet P-selectin (50–52). Rolling leukocytes
stop and firmly attach to adherent platelets when the
leukocyte integrin Mac-1 (CD11b/CD18) binds to platelet
glycoprotein Ib-alpha (53) or to fibrinogen bound to the
platelet glycoprotein IIb/IIIa (Fig. 1) (54). A direct role for
Mac-1 in leukocyte adhesion after mechanical injury has
been demonstrated in several experimental studies where
Mac-1 targeting reduces neointimal thickening after exper-
imental angioplasty (55,56). Clinical studies of patients
undergoing PCI further support the premise that Mac-1
and platelet-mediated leukocyte adhesion (also termed
“secondary capture”) plays an important role in vascular
inflammation and restenosis after coronary stenting. We
have previously shown that, compared with circulating
neutrophils, Mac-1 surface expression is significantly
increased in the neutrophils obtained from the coronary
sinus of patients who underwent PCI within the preced-
ing 48 h and that high levels of Mac-1 expression are
associated with angiographic late lumen loss and in-
creased risk of restenosis (57– 60). Increased Mac-1
expression also correlates with increased expression of
P-selectin on the surface of platelets obtained from the
Figure 1. Transplatelet Leukocyte Migration
At the site of stent implantation after percutaneous coronary intervention, end
blood. Platelets and ﬁbrinogen immediately adhere to the surface of the injure
leukocyte adhesion to the adherent platelets in a process termed “secondary c
let P-selectin and leukocyte P-selectin glycoprotein ligand (PSGL)-1. Arrest and
Mac-1. Chemokines stimulate transmigration into the extraluminal tissue.coronary sinus after PCI (57– 60).Role of Bone Marrow-Derived Stem Cells
in Restenosis and Vascular Repair
Emerging research is demonstrating that bone marrow-
derived progenitor cells play an important role in vascular
inflammation responses and in vascular repair. Endothelial
progenitor cells (EPCs) mobilized from bone marrow into
peripheral blood promote endothelial regeneration and post-
natal neovascularization (61,62). In contrast to the potential
protective effects of EPCs, it has been hypothesized that
smooth muscle progenitor cells (SMPCs), which are also
mobilized from bone marrow, migrate to the sites of
vascular injury where they contribute to smooth muscle cell
expansion and neointimal proliferation (63–65).
The precise function of EPCs and SMPCs once they
home to sites of vascular inflammation is controversial.
Previously, CD34-positive cells were believed to be com-
mitted to develop into EPCs; however, further study dem-
onstrated that the CD34 surface antigen actually identifies
undifferentiated bone marrow-derived stem cells that have
the ability to differentiate into EPC and SMPCs. Transdif-
ferentiation of CD34-positive cells into EPC or SMPC
lineages depends on the local environment; ischemic con-
ditions signal differentiation toward EPC phenotypes to
ial cells are denuded, and the subendothelial matrix is exposed to ﬂowing
sel. A multistep cascade of platelet and leukocyte adhesion molecules direct
e.” Leukocyte capture and rolling are mediated by interaction between plate-
dhesion are mediated by platelet glycoprotein (GP) Ib-alpha and leukocyteothel
d ves
aptur
ﬁrm apromote re-endothelialization (61,66), and inflammatory
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1061conditions signal differentiation toward SMPC phenotypes
that promote neointimal proliferation (63) (Fig. 2).
Several studies have implicated CD34-positive progeni-
tor cells in vascular injury responses after PCI. Circulating
CD34-positive cells are increased in the days after acute
myocardial infarction, and characterization of these circu-
lating cells suggests that they have an EPC-like phenotype,
raising the possibility that CD34-positive EPC-like cells are
mobilized to promote angiogenesis in the ischemic myocar-
dium. In contrast to ischemia-mediated mobilization,
SMPC-like CD34-positive cells increase after PCI in pa-
tients with chronic coronary artery disease, presumably in
response to inflammatory mediators produced at sites of
stent implantation (67). In this setting, elevated levels of
circulating CD34-positive cells are associated with in-
creased rates of restenosis, suggesting possible involvement
in neointimal formation (68).
We have also demonstrated that molecular signals gen-
erated at sites of local arterial inflammation promote the
mobilization of CD34-positive stem cells (69). In our study,
the number of CD34-positive cells in the peripheral blood
increased Day 7 to 14 after PCI, and patients who received
BMS had significantly more CD34-positive cells than those
who received DES (Fig. 3A) (69,70). Granulocyte colony-
stimulating factor (G-CSF) and Mac-1 levels were signifi-
cantly reduced in patients who underwent implantation of
DES, compared with those who received BMS, suggesting
Figure 2. Differentiation of Bone Marrow-Derived Stem Cells
Previously, CD34-positive cells were believed to be committed to develop
into EPCs; however, further study demonstrated that the CD34 surface anti-
gen actually identiﬁes undifferentiated bone marrow-derived stem cells
that have the ability to differentiate into EPC and SMPCs. Ischemic condi-
tions signal differentiation toward EPC phenotypes to promote re-endothe-
lialization. Inﬂammatory conditions signal differentiation toward SMPC
phenotypes that promote neointimal proliferation.that the antiproliferative stent drug attenuated inflamma-tory cell activation (Fig. 3B) (69). This observation is
consistent with our hypothesis that inflammatory signals
generated at sites of coronary injury mobilize bone marrow-
derived progenitor cells involved in vascular repair. To
further elucidate the role of CD34-positive cells in vascular
injury and repair after PCI, we isolated circulating CD34-
positive progenitor cells from patients who received DES
and BMS and performed in vitro differentiation assays
(Fig. 4) (69). In most patients, a proportion of the cultured
CD34-positive cells differentiated into both CD31-positive
endothelial-like cells and into alpha-actin-positive cells with
features suggestive of smooth muscle cell lineage. Several
other observations were made. First, the number of differ-
entiated colonies that formed from the CD34-positive cells
correlated with the extent of restenosis during angiographic
follow-up. Second, patients with more angiographic reste-
nosis had more CD34-positive cells that differentiated into
alpha-actin containing SMPC-like cells. Third, implanta-
tion of sirolimus-eluting stents resulted in reduced differ-
entiation of CD34-positive cells into CD31-positive cells
and reduced differentiation into alpha-actin-positive cells
with smooth muscle cell features. This finding is consistent
with in vitro data demonstrating that sirolimus inhibits
differentiation of human bone marrow-derived stem cells
into endothelial or smooth muscle cells (71,72).
Several lines of evidence support the premise that PCI
induces local inflammatory signals that mobilize bone
marrow-derived CD34-positive stem cells and that these
cells have the ability to differentiate along endothelial or
smooth muscle cell lines. In the setting of vascular injury,
there seems to be a balance between endothelial-like stem
cell responses that favor re-endothelialization and smooth
muscle-like stem cell responses that promote restenosis
(Fig. 2). Furthermore, it seems that, compared with BMS,
sirolimus-eluting stent implantation attenuates production
of local inflammatory signals that promote stem cell mobi-
lization and differentiation into smooth muscle-like cells
that contribute to neointimal proliferation. In the future,
targeted pharmacological therapies might be able to pro-
mote reparative progenitor cell responses and/or inhibit
responses that result in excess neointimal proliferation.
Local Vascular Inflammation
Signals Stem Cell Recruitment
As described in the preceding text, inflammatory and
hematopoietic cytokines produced locally at sites of
vascular inflammation direct mobilization of stem cells
from the bone marrow. Vascular-derived molecules in-
volved in stem cell mobilization include G-CSF, matrix
metalloproteinase-9, and stromal cell-derived factor
(SDF)-1.
G-CSF, a potent hematopoietic cytokine produced by
endothelium and immune cells, is expressed at sites of
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1062vascular injury (73). G-CSF promotes stem cell prolifera-
tion and mobilization, and it has been hypothesized that,
after PCI and/or myocardial infarction, G-CSF signals
production and homing of reparative stem cells that pro-
mote angiogenesis and myocardial repair. Clinical evalua-
tion of systemic G-CSF therapy after myocardial infarction
failed to show benefit in limiting infarct size or in improving
left ventricular function, despite its experimental effects on
stem mobilization (74,75). It is possible that the nonselec-
tive mobilization of both EPCs and SMPCs by G-CSF
might limit its therapeutic value for treating restenosis and
promoting vascular repair.
Neutrophil-derived matrix metalloproteinase-9 is an-
other inflammatory mediator that has a role in stem cell
mobilization (76). Matrix metalloproteinase-9 is secreted
locally in response to inflammatory inputs, including
ligand binding to the leukocyte integrin Mac-1 (77).
Matrix metalloproteinase-9 is required for G-CSF and
chemokine-induced mobilization of hematopoietic stem
cells from the bone marrow (78,79) and provides a
mechanism through which inflamed vascular beds gener-
ate systemic signals that promote bone marrow-derived
stem cell mobilization.
SDF-1 is a member of the CXC group of chemokines
that plays a role in stem cell plasticity and engraftment (80).
SDF-1 is expressed by smooth muscle cells at sites of
atherosclerosis and vascular inflammation. SDF-1 signals
Figure 3. CD34-Positive Cell Counts and CD34-Positive Cell Mac-1 Express
(A) Circulating CD34-positive cells increase after percutaneous coronary interv
blood of patients who received bare-metal stents that went on to have resten
Implantation of drug-eluting stent was associated with a signiﬁcant reduction
correlates with mobilization of CD34-positive cells. Forty-eight hours after PCI,
stents implanted. Neutrophil Mac-1 expression was quantiﬁed by ﬂow cytome
positive cells 7 days (d) after PCI, demonstrating that higher levels of local vas
tor cell mobilization. Data are expressed as percentage change of the baselinethe bone marrow to mobilize Sca-1 lineage progenitorells that home to sites of vascular injury where the
rogenitor cells adopt smooth muscle cell phenotypes. In
xperimental models, SDF-1 directly regulates neointimal
mooth muscle cell content, and inhibition of SDF-1
unction decreases neointimal formation (80). Therapies
argeting SDF-1 function could potentially inhibit resteno-
is after PCI.
odulating Vascular Injury and Repair:
ew Frontiers in DES Technology
Current-generation DES agents prevent restenosis by in-
hibiting smooth muscle cell proliferation. In developing the
next generation of DES agents it might be possible to
harness differential drug effects on smooth muscle cell
proliferation versus re-endothelialization in a manner that
could accelerate repair. Vascular endothelial growth factor
has attracted attention as a DES agent that could promote
endothelial regeneration and angiogenesis (81). Proof-of-
concept investigations have demonstrated that vascular en-
dothelial growth factor gene-eluting stents accelerate re-
endothelialization and reduce in-stent neointimal area in
animal models (82). Another new strategy to promote
vascular repair after PCI involves the use of antibodies (83)
or peptides (84) that bind membrane receptors on circulat-
ing endothelial progenitor cells. This strategy promotes
capture of these cells to accelerate healing (83). CD34
fter PCI
(PCI). The highest levels of CD34-positive cells were seen in the peripheral
t 6-month (m) angiographic follow-up (Bare-Metal Stent Restenosis ).
number of circulating CD34-positive cells. (B) Neutrophil Mac-1 expression
ophils were harvested from the coronary sinus of patients who had coronary
utrophil Mac-1 expression at 48 h correlated with circulating levels of CD34-
inﬂammation are associated with increased systemic CD34-positive progeni-
s. Adapted, with permission, from Inoue et al. (69).ion A
ention
osis a
in the
neutr
try. Ne
cularantibody-coated stents have been implanted in human
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1063coronary arteries in the multicenter HEALING (Healthy
Endothelial Accelerated Lining Inhibits neointimal Growth)
II pilot trial and in later follow-up studies (85,86). The
long-term safety and efficacy of this pro-healing stent
technology awaits further evaluation in randomized trials.
In addition to DES technology itself, adjunctive systemic
medications might also influence stem cell homing and the
balance between re-endothelialization and neointimal pro-
liferation. Interestingly, 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (statins) were recently shown to
promote EPC proliferation in vitro (87) and increase the
number of circulating EPCs in patients with coronary artery
disease (88). Despite initial optimism that statins might
favorably influence arterial healing after DES implantation,
enthusiasm has tempered after release of data showing that
high doses of statins started before PCI and continued
thereafter increased EPC mobilization but did not increase
circulating CD34 cells and did not improve the angio-
graphic outcome after implantation of a bioengineered
Figure 4. Differentiation of Patient-Derived CD34-Positive Stem Cells Into E
Circulating CD34-positive stem cells were isolated from peripheral blood of pa
stent (SES). Immunohistochemical staining for CD31 (A to D). (A) BMS without
cell clusters. Patients who received BMS had similar differentiation of CD34-po
they went on to have restenosis at 6-month angiographic follow-up. Patients
stem cells into CD31-positive endothelial-like cells, compared with patients tha
restenosis, (G) SES, (H) quantiﬁcation of actin positive cells. Patients who recei
increased numbers of CD34-positive stem cells that differentiated into actin-po
tion in the differentiation of CD34-positive stem cells into actin-positive smoot
resentative actin-positive cell. Adapted, with permission, from Inoue et al. (69)EPC-capture stent (89).Thiazolidinediones, which are used to treat diabetes,
function by activating peroxisome proliferator activating
receptor transcription factors. Several thiazolidinedione
agents increase the number of EPCs in both circulating
blood and bone marrow and reduce EPC apoptosis in a
phosphatidylinositol 3-kinase-dependent manner (90). Al-
though there are several potential vasculoprotective actions of
statins and thiazilidinediones, further clinical investigation will
be required to determine whether these medications will
positively influence vascular repair, resulting in reduced rates of
restenosis and enhanced re-endothelialization after PCI.
Conclusions
Percutaneous coronary intervention results in mechanical
injury that induces vascular inflammation. Vascular inflam-
mation involves complex interactions between endothelial
cells, smooth muscle cells, platelets, and inflammatory cells,
including neutrophils, monocytes, and lymphocytes. Signal-
elial-Like and Smooth Muscle-Like Cells After PCI
7 days (d) after implantation of bare-metal stent (BMS) or sirolimus-eluting
nosis, (B) BMS with restenosis, (C) SES, (D) quantiﬁcation of CD31-positive
stem cells into CD31-positive endothelial-like cells, regardless of whether
ceived SES had a signiﬁcant reduction in the differentiation of CD34-positive
ived BMS. Actin staining (E to H). (E) BMS without restenosis, (F) BMS with
MS and went on to have restenosis at 6-month angiographic follow-up had
smooth muscle-like cells. Patients who received SES had a signiﬁcant reduc-
scle-like cells, compared with patients that received BMS. Arrow denotes rep-ndoth
tients
reste
sitive
who re
t rece
ved B
sitive
h muing molecules produced by cells at the site of vascular injury
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1064stimulate mobilization of bone marrow-derived EPCs and
SMPCs, which are recruited to the sites of vascular inflam-
mation. The cellular and molecular processes that control
vascular injury responses direct repair and vascular healing;
however, dysregulation of these responses can result in
adverse arterial remodeling, neointimal proliferation, and
restenosis. Drug-eluting stents effectively reduce neointimal
proliferation but they slow re-endothelialization and heal-
ing. Drug-eluting stents also seem to influence the mobili-
zation, homing, and differentiation of reparative stem cells.
Despite the potential for DES-induced delayed vascular
healing, clinical trial investigations have demonstrated sim-
ilar safety of DES and BMS in the setting of extended dual
antiplatelet therapy. In the future, improved DES technolo-
gies have the potential to abolish restenosis and further
improve stent safety by inhibiting maladaptive neointimal
proliferation while promoting re-endothelialization and repair.
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